Literature DB >> 1895857

Iodine-125 seed implantation as an adjunct to surgery in advanced recurrent squamous cell cancer of the head and neck.

R I Park1, F Z Liberman, D J Lee, M M Goldsmith, J C Price.   

Abstract

Survival for extensive recurrent squamous cell carcinomas of the head and neck remains poor, with the major cause of death being local recurrence. Surgical implantation of iodine-125 interstitial seeds allows tumoricidal doses of radiation to be delivered to residual tumor while minimizing radiation doses to the surrounding tissues. From 1978 to 1988, 39 implantations were performed on 35 patients for extensive recurrent squamous cell carcinoma of the head and neck. The decision for implantation was based on positive margins or close to resection margins from frozen sections after salvage resection. The determinate 5-year disease-free survival was 41%, with both the overall and no evidence of disease 5-year survivals being 29%. Significant complications occurred in 36% of all cases. This figure increased to 56% when flap reconstruction was required. Possible reasons for this seemingly high complication rate are discussed. Considering the advanced nature of these recurrent carcinomas, surgical resection with iodine-125 seed implantation appears to be an effective method of managing disease that might otherwise be judged unresectable and treated for palliation only.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1895857     DOI: 10.1002/lary.1991.101.4.405

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  15 in total

1.  125I brachytherapy alone for recurrent or locally advanced adenoid cystic carcinoma of the oral and maxillofacial region.

Authors:  M-W Huang; L Zheng; S-M Liu; Y Shi; J Zhang; G-Y Yu; J-G Zhang
Journal:  Strahlenther Onkol       Date:  2013-04-28       Impact factor: 3.621

2.  CT-guided iodine-125 seed permanent implantation for recurrent head and neck cancers.

Authors:  Yu L Jiang; Na Meng; Jun J Wang; Ping Jiang; Hui Sh Yuan; Chen Liu; Ang Qu; Rui J Yang
Journal:  Radiat Oncol       Date:  2010-07-30       Impact factor: 3.481

3.  Interstitial 125I seeds implantation to treat spinal metastatic and primary paraspinal malignancies.

Authors:  Junjie Wang; Huishu Yuan; Qingjun Ma; Xiaoguang Liu; Hao Wang; Yuliang Jiang; Suqing Tian; Ruijie Yang
Journal:  Med Oncol       Date:  2009-04-10       Impact factor: 3.064

4.  CT-guided radioactive seed implantation for recurrent rectal carcinoma after multiple therapy.

Authors:  Jun Jie Wang; Hui Shu Yuan; Jin Na Li; Yu Liang Jiang; Su Qing Tian; Rui Jie Yang
Journal:  Med Oncol       Date:  2009-05-05       Impact factor: 3.064

5.  CT-guidance interstitial (125)Iodine seed brachytherapy as a salvage therapy for recurrent spinal primary tumors.

Authors:  Qianqian Cao; Hao Wang; Na Meng; Yuliang Jiang; Ping Jiang; Yang Gao; Suqing Tian; Chen Liu; Ruijie Yang; Junjie Wang; Kaixian Zhang
Journal:  Radiat Oncol       Date:  2014-12-23       Impact factor: 3.481

6.  Neither high-dose nor low-dose brachytherapy increases flap morbidity in salvage treatment of recurrent head and neck cancer.

Authors:  Peter W Henderson; David I Kutler; Bhupesh Parashar; David M Otterburn; Marc A Cohen; Jason A Spector
Journal:  J Contemp Brachytherapy       Date:  2016-08-29

7.  High-dose-rate interstitial brachytherapy in recurrent head and neck cancer: an effective salvage option.

Authors:  Rajendra Bhalavat; Vibhay Pareek; Manish Chandra; Lalitha Nellore; Karishma George; Dipalee Borade; Ketan Kalariya; Zaiba Moosa; Amrita Srivastava; Navaneeth Reddy; Ankita Kapoor; Darshana Kawale; Nandakumar P; Pratibha Bauskar
Journal:  J Contemp Brachytherapy       Date:  2018-10-15

8.  An investigation of 125I seed permanent implantation for recurrent carcinoma in the head and neck after surgery and external beam radiotherapy.

Authors:  Lihong Zhu; Yuliang Jiang; Junjie Wang; Weiqiang Ran; Huishu Yuan; Chen Liu; Ang Qu; Ruijie Yang
Journal:  World J Surg Oncol       Date:  2013-03-08       Impact factor: 2.754

9.  Cesium-131 brachytherapy in high risk and recurrent head and neck cancers: first report of long-term outcomes.

Authors:  Anthony Pham; Shruthi Arora; A Gabriella Wernicke; David I Kutler; Marc Cohen; William Kuhel; Samuel Trichter; Dattatreyudu Nori; Silvia C Formenti; Bhupesh Parashar
Journal:  J Contemp Brachytherapy       Date:  2015-12-30

10.  Clinical application of computed tomography-guided (125)I seed interstitial implantation for head and neck cancer patients with unmanageable cervical lymph node metastases.

Authors:  Hai Huang; Shaonian Xu; Fusheng Li; Zhenguang Du; Liang Wang
Journal:  Eur J Med Res       Date:  2016-04-27       Impact factor: 2.175

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.